05:38 AM EDT, 09/16/2026 (MT Newswires) -- BioPorto (BIOPOR.CO) enrolled the first patient in its validation study evaluating its ProNephro AKI urine test in adult patients with acute kidney injury, according to a Wednesday release. The ProNephro AKI US Adult Urine NGAL study, which follows the completion of an adult AKI cut-off study, will assess ProNephro AKI (NGAL)'s clinical performance for risk assessment of moderate-to-severe acute kidney injury in adult patients admitted to the intensive care unit. The in vitro diagnostics company plans to enroll 900 patients across multiple US clinical sites. ProNephro AKI (NGAL) is currently cleared by the US Food and Drug Administration for patients aged between three months and 21 years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.